GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Return-on-Tangible-Asset
中文

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Return-on-Tangible-Asset : -37.54% (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Regencell Bioscience Holdings Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Regencell Bioscience Holdings's annualized Net Income for the quarter that ended in Jun. 2023 was $-5.29 Mil. Regencell Bioscience Holdings's average total tangible assets for the quarter that ended in Jun. 2023 was $14.09 Mil. Therefore, Regencell Bioscience Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2023 was -37.54%.

The historical rank and industry rank for Regencell Bioscience Holdings's Return-on-Tangible-Asset or its related term are showing as below:

RGC' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -315.46   Med: -160.91   Max: -38.13
Current: -38.13

During the past 5 years, Regencell Bioscience Holdings's highest Return-on-Tangible-Asset was -38.13%. The lowest was -315.46%. And the median was -160.91%.

RGC's Return-on-Tangible-Asset is ranked worse than
81.35% of 1083 companies
in the Drug Manufacturers industry
Industry Median: 1.91 vs RGC: -38.13

Regencell Bioscience Holdings Return-on-Tangible-Asset Historical Data

The historical data trend for Regencell Bioscience Holdings's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Return-on-Tangible-Asset Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Return-on-Tangible-Asset
-160.91 -214.53 -315.46 -81.12 -38.32

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only -431.06 -67.11 -39.45 -38.45 -37.54

Competitive Comparison of Regencell Bioscience Holdings's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regencell Bioscience Holdings's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's Return-on-Tangible-Asset falls into.



Regencell Bioscience Holdings Return-on-Tangible-Asset Calculation

Regencell Bioscience Holdings's annualized Return-on-Tangible-Asset for the fiscal year that ended in Jun. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=-5.871/( (18.019+12.622)/ 2 )
=-5.871/15.3205
=-38.32 %

Regencell Bioscience Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=-5.288/( (15.548+12.622)/ 2 )
=-5.288/14.085
=-37.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Jun. 2023) net income data.


Regencell Bioscience Holdings  (NAS:RGC) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Regencell Bioscience Holdings Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Traded in Other Exchanges
N/A
Address
29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Headlines

From GuruFocus